Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRSD107 in Chronic Coronary and/or Peripheral Artery Disease (Phase 2a)
CTR20255127Phase 2Active
- Sponsor
- Jingyin Biopharma
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis and arteriosclerosis obliterans comparing SRSD107 with Placebo (0.9% sodium chloride) (2 arms). Primary endpoint: Time-averaged percentage change from baseline in factor XI antigen. Started Mar 2026; status: active.
02
Drugs
SRSD107
03
Conditions
coronary arteriosclerosisarteriosclerosis obliterans
Beyond the preview
Go deeper on CTR20255127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255127.